<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892148</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-428</org_study_id>
    <secondary_id>2018-A02971-54</secondary_id>
    <nct_id>NCT03892148</nct_id>
  </id_info>
  <brief_title>Protocol of Diuretics Use in Congestive Therapy in Heart Failure</brief_title>
  <acronym>ProDUCT-HF</acronym>
  <official_title>Evaluation of an Optimization Protocol for Diuretics in the Decompensation of Chronic Heart Failure: Randomized Trial in Clusters With Sequential Permutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HÃ´pital de la Croix-Rousse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Puy en Velay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Moulins-Yzeure</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Riom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infirmerie Protestante de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Issoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Annecy Genevois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to determine if a diuretic adaptation protocol in the
      decompensation of chronic heart failure is more effective but also safer than the current
      non-protocolized practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diuretics are the main treatment for congestive decompensation of chronic heart failure. For
      symptomatic purposes, the goal is to decrease the volume overload. In these patients, loop
      diuretics are used in high doses, sometimes in combination with other classes of diuretics
      such as thiazides to achieve synergistic, faster and more effective action, and to combat
      diuretic's resistance. This use, well known to cardiologists and based on a rich
      pharmacology, more than 40 years old, lacks robust scientific data in real life. Current
      studies are mainly based on patients with renal insufficiency or limited to cardio-renal
      syndrome. The CARRESS-H study in 2012 is one of them. The protocol for the use of diuretics
      from this study was included in 2017 as a benchmark in a publication of the NEJM. It
      therefore seems necessary to consider the exercise of this protocol in the management of the
      decompensation of chronic cardiac heart failure. There is, to the investigator's knowledge,
      no similar study to test this protocol as a &quot;real life&quot; exercise.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the serum creatinine level</measure>
    <time_frame>at day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in weight</measure>
    <time_frame>at day 1</time_frame>
    <description>The weight will be measured in kilograms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of intravenous administration of diuretics</measure>
    <time_frame>at day 1</time_frame>
    <description>Length of time of intravenous administration of diuretics in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of acute kidney injury during hospitalisation</measure>
    <time_frame>at day 1</time_frame>
    <description>Acute kidney injury requiring interruption of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Hypokaliemia</measure>
    <time_frame>at day 1</time_frame>
    <description>Severe hypokalaemia means hypokalaemia that requiring interruption of treatment, dialysis or transfer in intensive care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of rehospitalization for heart failure or kidney failure</measure>
    <time_frame>At 30 days after the date of randomisation</time_frame>
    <description>Number of rehospitalization for heart failure or kidney failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (all cause and heart failure)</measure>
    <time_frame>At 30 days after the date of randomisation</time_frame>
    <description>Number of death of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of diuretics</measure>
    <time_frame>At 30 days after the date of randomisation</time_frame>
    <description>Comparison of diuretics dose of Furosemide and/or Thiazid diuretic. The dose will be measured on milligrams per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description and comparison of global cost between the two groups</measure>
    <time_frame>At 30 days after the date of randomisation</time_frame>
    <description>Description and comparison of global cost between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated plasma volume change</measure>
    <time_frame>At 30 days after the date of randomisation</time_frame>
    <description>Estimated plasma volume change captured via hemoglobin-to-hematocrit ratio (Hb/Ht) using the Strauss formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in bodyweight</measure>
    <time_frame>at 96 hours after randomization</time_frame>
    <description>The weight will be measured in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood chemistry (serum creatinine)</measure>
    <time_frame>month 1</time_frame>
    <description>serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood chemistry (glomerular filtration rate)</measure>
    <time_frame>month 1</time_frame>
    <description>glomerular filtration rate (GFR) estimated using the CKD-EPI equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood chemistry</measure>
    <time_frame>month 1</time_frame>
    <description>NT-proBNP or BNP (as available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood chemistry (plasma volume estimated)</measure>
    <time_frame>month 1</time_frame>
    <description>plasma volume estimated via hemoglobin-to-hematocrit ratio (Hb/Ht)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Failure</condition>
  <condition>Acute Heart Failure</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of loop diuretics and thiazide diuretics leaves to the discretion of the responsible physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use of loop diuretics and thiazide diuretics according to the CARRESS-HF protocol developed by the Heart Failure Network</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Protocol for the use of diuretics</description>
    <arm_group_label>Protocol</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Protocol for the use of diuretics</description>
    <arm_group_label>Protocol</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients hospitalized for chronic decompensated congestive heart failure without
             acute pulmonary edema and acute cardiac decompensation against a background of
             hypertensive crisis

          -  covered under a social security program

          -  with legal capacity to give voluntary informed consent to participate in the study

        Exclusion Criteria:

          -  First episode of decompensated congestive heart failure

          -  Protocolized shock or hypotension (&lt;90 mmHg blood pressure) managed or requiring
             nitrovasodilators or non-invasive ventilation

          -  One of the following cardiovascular pathologies: acute myocardial infarction / cardiac
             tamponade / aortic dissection / acute pulmonary embolism / heart transplant /
             ventricular assist device / acute pulmonary edema / hypertensive crisis

          -  More than 12h of intravenous diuretics administered prior to inclusion

          -  Generalized edema caused by cirrhosis or nephrotic syndrome

          -  Requiring pleural or peritoneal tap for therapeutic purposes

          -  Patient allergic or intolerant to furosemide and on long-term bumetanide use

          -  Patient in dialysis or end-stage chronic kidney disease (CKD-EPI-calculated GFR &lt;15
             mL/min/1.73mÂ²) or acute kidney injury of known non-cardiac cause

          -  Severe hypokalemia (&lt; 3 mmol/L) on admission

          -  Patient who is pregnant, breastfeeding, or of childbearing age not on effective
             contraception

          -  Adult patient safeguarded under court protection measures (guardianship, wardship, or
             judicial protection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume CLERFOND</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>04 73 75 49 63</phone>
    <email>drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ch Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mathieu CHACORNAC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise LACLAUTRE</last_name>
      <phone>04 73 75 49 63</phone>
      <email>drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume CLERFOND</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain ESCHALIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal MOTREFF</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>GÃ©rald VANZETTO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Issoire</name>
      <address>
        <city>Issoire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Youssef NAHLI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH PUY</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier DE TAURIAC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infirmerie Protestante de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Salim MADI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brahim HARBAOUI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Moulins</name>
      <address>
        <city>Moulins</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hassan BARAKE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH RIOM</name>
      <address>
        <city>Riom</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurence FLORK</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Diuretics</keyword>
  <keyword>Diuretic resistance</keyword>
  <keyword>Loop diuretics</keyword>
  <keyword>Furosemide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

